SHIFT Newsroom · UK

MHRA strengthens antidepressant safety information

Catch-up: safety communication published 15 October 2026.

By SHIFT Newsroom · Published 19 October 2026 · Updated 20 October 2026

How we prepare and check newsroom articles · Report a correction

The MHRA announced clearer warnings about suicidal thoughts and behaviours, and sexual dysfunction that can persist after treatment. Measures include a boxed warning in patient leaflets, a patient card and the term post-SSRI sexual dysfunction in leaflets for certain medicines. A supporting safety leaflet is planned for 2027. These are clearer communications about existing risks, not newly discovered risks.

SHIFT’s take

What we think this could mean for you, and what remains uncertain.

Patients need clear benefits-and-risks information; this announcement is not a reason to abandon effective treatment.

Known facts

The supporting safety leaflet is planned for 2027.

Sources and evidence

MHRA — Source date: 15 October 2026

← Back to SHIFT Newsroom